ReGen Biologics Announces Closing of Additional Financing

HACKENSACK, N.J.–(BUSINESS WIRE)–ReGen Biologics (OTC: RGBO – News) (“ReGen” or the “Company”) announced today that it recently completed the second of a two stage private placement of approximately $1.7 million in common stock for combined gross proceeds of approximately $9 million. The proceeds will support the launch of the Company’s Menaflex™ collagen meniscus implant device in the U.S., which recently received FDA clearance.

“This financing marks a successful conclusion to the first stage of our U.S. commercialization funding strategy,” said Gerald E. Bisbee, Jr., Ph.D., Chairman and CEO. “We appreciate the financial support that we have enjoyed from many long-term ReGen investors,” Dr. Bisbee continued.

Josh Sandberg

Josh Sandberg is the President of Ortho Spine Partners and Partner for The De Angelis Group. He also serves as Co-Founder and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button